Abstract
6-Hydroxydopamine (6-OHDA), which is a neurotoxin that selectively destroys catecholaminergic nerves in sympathetically innervated tissues, has been used to provide a model of Parkinson’s disease in experimental animals. It is rapidly autoxidised to yield potentially toxic products and reactive oxygen species. Its ability to release Fe(II) from protein storage sites also results in the formation of hROS. This account will consider how this family of toxic products may contribute to the observed effects of 6-OHDA.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- aCSF:
-
Artificial cerebrospinal fluid
- HNE:
-
4-Hydroxynonenal
- hROS:
-
Highly reactive oxygen species
- MAO:
-
Monoamine oxidase
- PBD:
-
Phosphate-buffered saline
- 6-OHDA:
-
6-Hydroxydopamine
- ROS:
-
Reactive oxygen species
References
Abad F, Maroto R, López MG, Sánchez-García P, García AG (1995) Pharmacological protection against the cytotoxicity induced by 6-hydroxydopamine and H2O2 in chromaffin cells. Eur J Pharmacol 293:55–64. https://doi.org/10.1016/0926-6917(95)90018-7
Alegría AE, Sanchez-Cruz P, Rivas L (2004) Alkaline-earth cations enhance ortho-quinone-catalyzed ascorbate oxidation. Free Radic Biol Med 37:1631–1639. https://doi.org/10.1016/j.freeradbiomed.2004.07.030
Anastasiou D, Poulogiannis G, Asara JM, Boxer MB, Jiang JK, Shen M et al (2011) Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 334:1278–1283. https://doi.org/10.1126/science.1211485
Andrew R, Watson DG, Best SA, Midgley JM, Wenlong H, Petty RK (1993) The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls. Neurochem Res 18:1175–1177. https://doi.org/10.1007/bf00978370
Baker G, Matveychuk D, MacKenzie EM, Holt A, Wang Y, Kar S (2019) Attenuation of the effects of oxidative stress by the MAO-inhibiting antidepressant and carbonyl scavenger phenelzine. Chem Biol Interact 304:139–147. https://doi.org/10.1016/j.cbi.2019.03.003
Bar-Am O, Amit T, Youdim MBH (2007) Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro. J Neurochem 103:500–508. https://doi.org/10.1111/j.1471-4159.2007.04777.x
Barreto JC, Smith GS, Strobel NH, McQuillin PA, Miller TA (1995) Terephthalic acid: a dosimeter for the detection of hydroxyl radicals in vitro. Life Sci 56:89–96. https://doi.org/10.1016/0024-3205(94)00925-2
Ben-Shachar D, Eshel G, Finberg JP, Youdim MBH (1991) The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem 56:1441–1444. https://doi.org/10.1111/j.1471-4159.1991.tb11444.x
Ben-Shachar D, Zuk R, Gazawi H, Ljubuncic P (2004) Dopamine toxicity involves mitochondrial complex I inhibition: implications to dopamine-related neuropsychiatric disorders. Biochem Pharmacol 67:1965–1974. https://doi.org/10.1016/j.bcp.2004.02.015
Benvenutti R, Marcon M, Reis CG, Nery LR, Miguel C, Herrmann AP, Vianna MRM, Piato A (2018) N-Acetylcysteine protects against motor, optomotor and morphological deficits induced by 6-OHDA in zebrafish larvae. PeerJ 6:e4957. https://doi.org/10.7717/peerj.4957
Biosa A, Arduini I, Soriano ME, Giorgio V, Bernardi P, Bisaglia M, Bubacco L (2018) Dopamine oxidation products as mitochondrial endotoxins, a potential molecular mechanism for preferential neurodegeneration in Parkinson's disease. ACS Chem Neurosci 9:2849–2858. https://doi.org/10.1021/acschemneuro.8b00276
Bisaglia M, Mammi S, Bubacco L (2007) Kinetic and structural analysis of the early oxidation products of dopamine: analysis of the interactions with alpha-synuclein. J Biol Chem 282:15597–15605. https://doi.org/10.1074/jbc.M610893200
Blackinton J, Lakshminarasimhan M, Thomas KJ, Ahmad R, Greggio E, Raza AS, Cookson MR, Wilson MA (2009) Formation of a stabilized cysteine sulfinic acid is critical for the mitochondrial function of the parkinsonism protein DJ-1. J Biol Chem 284:6476–6485. https://doi.org/10.1074/jbc.M806599200
Blanchard-Fillion B, Souza JM, Friel T, Jiang GC, Vrana K, Sharov V, Barrón L, Schöneich C, Quijano C, Alvarez B, Radi R, Przedborski S, Fernando GS, Horwitz J, Ischiropoulos H (2001) Nitration and inactivation of tyrosine hydroxylase by peroxynitrite. Biol Chem 276:46017–46023. https://doi.org/10.1074/jbc.M105564200
Blandini F, Armentero MT, Fancellu R, Blaugrund E, Nappi G (2004) Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. Exp Neurol 187:455–459. https://doi.org/10.1016/j.expneurol.2004.03.005
Blandini F, Armentero MT, Martignoni E (2008) 6-Hydroxydopamine model: news from the past. Parkinsonism Relat Disord 14(Suppl 2):S124–129. https://doi.org/10.1016/j.parkreldis.2008.04.015
Blum D, Torch S, Nissou MF, Benabid AL, Verna JM (2000) Extracellular toxicity of 6-hydroxydopamine on PC12 cells. Neurosci Lett 283:193–196. https://doi.org/10.1016/s0304-3940(00)00948-4
Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R, Verna JM (2001) Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 65:135–172
Borah A, Mohanakumar KP (2009) Long term l-DOPA treatment causes production of 6-OHDA in the mouse striatum: involvement of hydroxyl radical. Ann Neurosci 16:160–165. https://doi.org/10.5214/ans.0972.7531.2009.160406
Borah A, Mohanakumar KP (2010) Salicylic acid protects against chronic l-DOPA-induced 6-OHDA generation in experimental model of parkinsonism. Brain Res 1344:192–199. https://doi.org/10.1016/j.brainres.2010.05.010
Borchardt RT, Reid JR, Thakker DR (1976) Catechol O-methyltransferase. 9. Mechanism of inactivation by 6-hydroxydopamine. J Med Chem 19:1201–1209. https://doi.org/10.1021/jm00232a007
Borisenko GG, Kagan VE, Hsia CJ, Schor NF (2000) Interaction between 6-hydroxydopamine and transferrin: "Let my iron go". Biochemistry 39(12):3392–3400. https://doi.org/10.1021/bi992296v
Bruchelt G, Buck J, Girgert R, Treuner J, Niethammer D (1985) The role of reactive oxygen compounds derived from 6-hydroxydopamine for bone marrow purging from neuroblastoma cells. Biochem Biophys Res Commun 130:168–174. https://doi.org/10.1016/0006-291x(85)90397-3
Cagnol S, Chambard JC (2010) ERK and cell death: mechanisms of ERK-induced cell death—apoptosis, autophagy and senescence. FEBS J 277:2–21. https://doi.org/10.1111/j.1742-4658.2009.07366.x
Carballo-Carbajal I, Laguna A, Romero-Giménez J, Cuadros T, Bové J, Martinez-Vicente M, Parent A et al (2019) Brain tyrosinase overexpression implicates age-dependent neuromelanin production in Parkinson's disease pathogenesis. Nat Commun 10:973. https://doi.org/10.1038/s41467-019-08858-y
Cerruti C, Drian MJ, Kamenka JM, Privat A (1993) Protection by BTCP of cultured dopaminergic neurons exposed to neurotoxins. Brain Res 617:138–142. https://doi.org/10.1016/0006-8993(93)90624-v
Chen C, Turnbull DM, Reeve AK (2019) Mitochondrial dysfunction in Parkinson's disease-cause or consequence? Biology (Basel). https://doi.org/10.3390/biology8020038
Cheng SY, Wang SC, Lei M, Wang Z, Xiong K (2018) Regulatory role of calpain in neuronal death. Neural Regen Res 13:556–562. https://doi.org/10.4103/1673-5374.228762
Choi WS, Yoon SY, Oh TH, Choi EJ, O'Malley KL, Oh YJ (1999) Two distinct mechanisms are involved in 6-hydroxydopamine- and MPP+-induced dopaminergic neuronal cell death: role of caspases, ROS, and JNK. J Neurosci Res 57:86–94. https://doi.org/10.1002/(SICI)1097-4547(19990701)57:1%3c86:AID-JNR9%3e3.0.CO;2-E
Chuang DM, Hough C, Senatorov VV (2005) Glyceraldehyde-3-phosphate dehydrogenase, apoptosis, and neurodegenerative diseases. Annu Rev Pharmacol Toxicol 45:269–290. https://doi.org/10.1146/annurev.pharmtox.45.120403.095902
Commins DL, Shaughnessy RA, Axt KJ, Vosmer G, Seiden LS (1989) Variability among brain regions in the specificity of 6-hydroxydopamine (6-OHDA)-induced lesions. J Neural Transm (Vienna) 77:197–210. https://doi.org/10.1007/bf01248932)
Couée I, Tipton KF (1991) The sulphydryl groups of ox brain and liver glutamate dehydrogenase preparations and the effects of oxidation on their inhibitor sensitivities. Neurochem Res 16:773–780. https://doi.org/10.1007/bf00965686
Curtius HC, Wolfensberger M, Steinmann B, Redweik U, Siegfried J (1974) Mass fragmentography of dopamine and 6-hydroxydopamine. Application to the determination of dopamine in human brain biopsies from the caudate nucleus. J Chromatogr 99:529–540. https://doi.org/10.1016/s0021-9673(00)90882-3
Cutillas B, Ambrosio S, Unzeta M (9601N) Neuroprotective effect of the monoamine oxidase inhibitor PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] on rat nigral neurons after 6-hydroxydopamine-striatal lesion. Neurosci Lett 329:165–168. https://doi.org/10.1016/s0304-3940(02)00614-6
Dajas-Bailador FA, Martinez-Borges A, Costa G, Abin JA, Martignoni E, Nappi G, Dajas F (1998) Hydroxyl radical production in the substantia nigra after 6-hydroxydopamine and hypoxia-reoxygenation. Brain Res 813:18–25. https://doi.org/10.1016/s0006-8993(98)00989-5
D'Arcy MS (2019) Cell death: a review of the major forms of apoptosis, necrosis and autophagy. Cell Biol Int 43:582–592. https://doi.org/10.1002/cbin.11137
Decker DE, Althaus JS, Buxser SE, VonVoigtlander PF, Ruppel PL (1993) Competitive irreversible inhibition of dopamine uptake by 6-hydroxydopamine. Res Commun Chem Pathol Pharmacol 79:195–208
Deumens R, Blokland A, Prickaerts J (2003) Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exper Neurol 175:303–317. https://doi.org/10.1006/exnr.2002.7891
Dexter DT, Carayon A, Javoy-Agid F, Agid Y (1991) Wells, FR (1991) Levels of iron, ferritin and other trace elements in Parkinson’s disease and in other neurodegenerative diseases affecting the basal ganglia. Brain 114:1953–1975
Dexter DT, Statton SA, Whitmore C, Freinbichler W, Weinberger P, Tipton KF, Della Corte L, Ward RJ, Crichton RR (2011) Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration. J Neural Transm (Vienna) 118:223–231. https://doi.org/10.1007/s00702-010-0531-3
Dimpfel W, Hoffmann JA (2011) Effects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in the rat hippocampus slice in vitro. BMC Pharmacol 21(11):2. https://doi.org/10.1186/1471-2210-11-2
Dorn GW 2nd (2013) Molecular mechanisms that differentiate apoptosis from programmed necrosis. Toxicol Pathol 41:227–234. https://doi.org/10.1186/1471-2210-11-2
Elkon H, Melamed E, Offen D (2001) 6-Hydroxydopamine increases ubiquitin-conjugates and protein degradation: implications for the pathogenesis of Parkinson's disease. Cell Mol Neurobiol 21:771–781. https://doi.org/10.1385/JMN:24:3:387
Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82:70–77. https://doi.org/10.1016/0003-9861(59)90090-6
Emamzadeh FN (2016) Alpha-synuclein structure, functions, and interactions. J Res Med Sci 21:29. https://doi.org/10.4103/1735-1995.181989
Enyedy IJ, Sakamuri S, Zaman WA, Johnson KM, Wang S (2003) Pharmacophore-based discovery of substituted pyridines as novel dopamine transporter inhibitors. Bioorg Med Chem Lett 13:513–517. https://doi.org/10.1016/s0960-894x(02)00943-5
Ferger B, Rose S, Jenner A, Halliwell B, Jenner P (2001a) 6-hydroxydopamine increases hydroxyl free radical production and DNA damage in rat striatum. NeuroReport 12:1155–1159. https://doi.org/10.1046/j.1471-4159.2001.00429.x
Ferger B, Themann C, Rose S, Halliwell B, Jenner P (2001b) The 6-hydroxydopamine increases the hydroxylation and nitration of phenylalanine in vivo: implication of peroxynitrite formation. J Neurochem 78:509–514. https://doi.org/10.1046/j.1471-4159.2001.00429.x
Floris G, Medda R, Padiglia A, Musci G (2000) The physiopathological significance of ceruloplasmin. A possible therapeutic approach. Biochem Pharmacol 60:1735–1741. https://doi.org/10.1016/s0006-2952(00)00399-3
Forman HJ (2007) Use and abuse of exogenous H2O2 in studies of signal transduction. Free Radic Biol Med 42:926–932. https://doi.org/10.1016/j.freeradbiomed.2007.01.01
Freinbichler W, Tipton KF, Della Corte LD, Linert W (2009) Mechanistic aspects of the Fenton reaction under conditions approximated to the extracellular fluid. J Inorg Biochem 103:28–34. https://doi.org/10.1016/j.jinorgbio.2008.08.014
Freinbichler W, Colivicchi MA, Stefanini C, Bianchi L, Ballini C, Misini B, Weinberger P, Linert W, Varešlija D, Tipton KF, Della Corte L (2011) Highly reactive oxygen species: detection, formation, and possible functions. Cell Mol Life Sci 68:2067–2079. https://doi.org/10.1007/s00018-011-0682-x
Freinbichler W, Misini B, Colivicchi MA, Linert W, Tipton KF, Della Corte L (2020) The application of bathophenanthroline for the determination of free iron in parallel with hROS in microdialysis samples. J Neurosci Methods. https://doi.org/10.1016/j.jneumeth.2019.108530
Gee P, Davison AJ (1989) Intermediates in the aerobic autoxidation of 6-hydroxydopamine: relative importance under different reaction conditions. Free Radic Biol 6:271–284. https://doi.org/10.1016/0891-5849(89)90054-3
Gerlach M, Double KL, Ben-Shachar D, Zecca L, Youdim MBH, Riederer P (2003) Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease. Neurotox Res 5(1–2):35–44
Giordano S, Lee J, Darley-Usmar VM, Zhang J (2012) Distinct effects of rotenone, 1-methyl-4-phenylpyridinium and 6-hydroxydopamine on cellular bioenergetics and cell death. PLoS ONE 7:e44610. https://doi.org/10.1371/journal.pone.0044610
Glinka YY, Youdim MBH (1995) Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. Eur J Pharmacol 292:329–332. https://doi.org/10.1016/0926-6917(95)90040-3
Glinka Y, Tipton KF, Youdim MBH (1996) Nature of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine. J Neurochem 66:2004–2010. https://doi.org/10.1046/j.1471-4159.1996.66052004.x
Gonçalves DF, Courtes AA, Hartmann DD, da Rosa PC, Oliveira DM, Soares FAA, Dalla Corte CL (2019) 6-Hydroxydopamine induces different mitochondrial bioenergetics response in brain regions of rat. Neurotoxicology 70:1–11. https://doi.org/10.1016/j.neuro.2018.10.005
Gough DR, Cotter TG (2011) Hydrogen peroxide: a Jekyll and Hyde signalling molecule. Cell Death Dis 2:e213. https://doi.org/10.1038/cddis.2011.96
Graham DG (1978) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14:633–643
Guo JD, Zhao X, Li Y, Li GR, Liu XL (2018) Damage to dopaminergic neurons by oxidative stress in Parkinson's disease. Int J Mol Med 41:1817–1825. https://doi.org/10.3892/ijmm.2018.3406
Gupta V, Carroll KS (2014) Sulfenic acid chemistry, detection and cellular lifetime. Biochim Biophys Acta 1840:847–875. https://doi.org/10.1016/j.bbagen.2013.05.040
Hanrott K, Gudmunsen L, O'Neill MJ, Wonnacott S (2006) 6-Hydroxydopamine-induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase Cdelta. J Biol Chem 281:5373–5382. https://doi.org/10.1074/jbc.M511560200
Hansson C, Rorsman H, Rosengren E (1981) Pronounced formation of 5-OH-dopa at enzymatic oxidation of DOPA in the presence of ascorbic acid. Acta Derm Venereol 61:147–148
Hartmann C, McIntire WS (1997) Amine-oxidizing quinoproteins. Methods Enzymol 280:98–150. https://doi.org/10.1016/s0076-6879(97)80106-1
Hayes JP, Tipton KF (2002) Interactions of the neurotoxin 6-hydroxydopamine with glyceraldehyde-3-phosphate dehydrogenase. Toxicol Lett 128:197–206. https://doi.org/10.1016/s0378-4274(02)00013-9
He X, Yuan W, Li Z, Feng J (2017) An autophagic mechanism is involved in the 6-hydroxydopamine-induced neurotoxicity in vivo. Toxicol Lett 280:29–40. https://doi.org/10.1016/j.toxlet.2017.08.006
Heikkila RE, Cohen G (1973) 6-Hydroxydopamine: evidence for superoxide radical as an oxidative intermediate. Science 181:456–457. https://doi.org/10.1126/science.181.4098.456
Heinonen E, Akerman KE (1986) Measurement of cytoplasmic, free magnesium concentration with entrapped eriochrome blue in nerve endings isolated from the guinea pig brain. Neurosci Lett 72:105–110. https://doi.org/10.1016/0304-3940(86)90627-0
Henze C, Earl C, Sautter J, Schmidt N, Themann C, Hartmann A, Oertel WH (2005) Reactive oxidative and nitrogen species in the nigrostriatal system following striatal 6-hydroxydopamine lesion in rats. Brain Res 1052:97–104. https://doi.org/10.1016/j.brainres.2005.06.020
Herraiz T, González D, Ancín-Azpilicueta C, Arán VJ, Guillén H (2010) Beta-carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO). Food Chem Toxicol 48:839–845. https://doi.org/10.1016/j.fct.2009.12.019
Hill RL, Kulbe JR, Singh IN, Wang JA, Hall ED (2018) Synaptic mitochondria are more susceptible to traumatic brain injury-induced oxidative damage and respiratory dysfunction than non-synaptic mitochondria. Neuroscience 386:265–283. https://doi.org/10.1016/j.neuroscience.2018.06.028
Holtz WA, O'Malley K (2003) Parkinsonian mimetics induce aspects of unfolded protein response in death of dopaminergic neurons. J Biol Chem 278:19367–19377. https://doi.org/10.1074/jbc.M211821200
Holtz WA, Turetzky JM, O'Malley KL (2005) Microarray expression profiling identifies early signaling transcripts associated with 6-OHDA-induced dopaminergic cell death. Antioxid Redox Signal 7:639–648. https://doi.org/10.1089/ars.2005.7.639
Holtz WA, Turetzky JM, Jong YJ, O'Malley KL (2006) Oxidative stress-triggered unfolded protein response is upstream of intrinsic cell death evoked by parkinsonian mimetics. J Neurochem 99:54–69. https://doi.org/10.1111/j.1471-4159.2006.04025.x
Huang J, Hao L, Xiong N, Cao X, Liang Z, Sun S, Wang T (2009) Involvement of glyceraldehyde-3-phosphate dehydrogenase in rotenone-induced cell apoptosis: relevance to protein misfolding and aggregation. Brain Res 1279:1–8. https://doi.org/10.1016/j.brainres.2009.05.011
Hwang NR, Yim S-H, Kim YM, Jeong J, Song EJ, Lee Y, Lee JH, Choi S, Lee K-J (2009) Oxidative modifications of glyceraldehyde-3-phosphate dehydrogenase play a key role in its multiple cellular functions. Biochem J 423:253–264. https://doi.org/10.1042/BJ20090854253
Iglesias-González J, Sánchez-Iglesias S, Méndez-Álvarez E, Rose S, Hikima A, Jenner P, Soto-Otero R (2012) Differential toxicity of 6-hydroxydopamine in SH-SY5Y human neuroblastoma cells and rat brain mitochondria: protective role of catalase and superoxide dismutase. Neurochem Res 37:2150–2160. https://doi.org/10.1007/s11064-012-0838-6
Inaba-Hasegawa K, Shamoto-Nagai M, Maruyama W, Naoi M (2017) Type B and A monoamine oxidase and their inhibitors regulate the gene expression of Bcl-2 and neurotrophic factors in human glioblastoma U118MG cells: different signal pathways for neuroprotection by selegiline and rasagiline. J Neural Transm (Vienna) 124:1055–1066. https://doi.org/10.1007/s00702-017-1740-9
Izumi Y, Sawada H, Sakka N, Yamamoto N, Kume T, Katsuki H, Shimohama S, Akaike A (2005) p-Quinone mediates 6-hydroxydopamine-induced dopaminergic neuronal death and ferrous iron accelerates the conversion of p-quinone into melanin extracellularly. J Neurosci Res 79:849–860. https://doi.org/10.1002/jnr.20382
Jameson GN, Jameson RF, Linert W (2004a) New insights into iron release from ferritin: direct observation of the neurotoxin 6-hydroxydopamine entering ferritin and reaching redox equilibrium with the iron core. Org Biomol Chem. 2(16):2346–2351. https://doi.org/10.1039/B408044K
Jameson GN, Zhang J, Jameson RF, Linert W (2004b) Kinetic evidence that cysteine reacts with dopaminoquinone via reversible adduct formation to yield 5-cysteinyl-dopamine: an important precursor of neuromelanin. Org Biomol Chem 2:777–782. https://doi.org/10.1039/b316294j
Jellinger K, Linert L, Kienzl E, Herlinger E, Youdim MBH (1997) Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease. J Neural Transm (Vienna) Suppl 46:297–314
Ji Y, Bennett BM (2003) Activation of microsomal glutathione S-transferase by peroxynitrite. Mol Pharmacol 63:136–146. https://doi.org/10.1124/mol.63.1.136
Jinsmaa Y, Florang VR, Rees JN, Anderson DG, Strack S, Doorn JA (2009) Products of oxidative stress inhibit aldehyde oxidation and reduction pathways in dopamine catabolism yielding elevated levels of a reactive intermediate. Chem Res Toxicol 22:835–841. https://doi.org/10.1021/tx800405v
Jonsson G, Sachs C (1971) Uptake and accumulation of 3H–6-hydroxydopamine in adrenergic nerves. Eur J Pharmacol 16:55–62. https://doi.org/10.1016/0014-2999(71)90056-2
Khan FH, Sen T, Chakrabarti S (2003) Dopamine oxidation products inhibit Na+, K+-ATPase activity in crude synaptosomal-mitochondrial fraction from rat brain. Free Radic Res 37:597–601. https://doi.org/10.1016/j.bbadis.2005.03.013
Kim DH, Jang YY, Han ES, Lee CS (2001) Protective effect of harmaline and harmalol against dopamine- and 6-hydroxydopamine-induced oxidative damage of brain mitochondria and synaptosomes, and viability loss of PC12 cells. Eur J 13:1861–1872. https://doi.org/10.1046/j.0953-816x.2001.01563.x
Kinnally KW, Peixoto PM, Ryu SY, Dejean LM (2011) Is mPTP the gatekeeper for necrosis, apoptosis, or both? Biochim Biophys Acta 1813:616–622. https://doi.org/10.1016/j.bbamcr.2010.09.013
Knapp DJ, Breese GR (2016) The use of perinatal 6-hydroxydopamine to produce a rodent model of Lesch-Nyhan disease. Curr Top Behav Neurosci 29:265–277. https://doi.org/10.1007/7854_2016_444
Knight KL, Mudd JB (1984) The reaction of ozone with glyceraldehyde-3-phosphate dehydrogenase. Arch Biochem Biophys 229:259–269. https://doi.org/10.1016/0003-9861(84)90152-8
Kostrzewa JP, Kostrzewa RA, Kostrzewa RM, Brus R, Nowak P (2016) Perinatal 6-hydroxydopamine modeling of ADHD. Curr Top Behav Neurosci 29:279–293. https://doi.org/10.1007/7854_2015_397
Kuhn DM, Sadidi M, Liu X, Kreipke C, Geddes T, Borges C, Watson JT (2002) Peroxynitrite-induced nitration of tyrosine hydroxylase: identification of tyrosines 423, 428, and 432 as sites of modification by matrix-assisted laser desorption ionization time-of-flight mass spectrometry and tyrosine-scanning mutagenesis. J Biol Chem 27:14336–21442. https://doi.org/10.1074/jbc.M200290200
Kulich SM, Horbinski C, Patel M, Chu CT (2007) 6-Hydroxydopamine induces mitochondrial ERK activation. Free Radic Biol Med 43:372–383. https://doi.org/10.1016/j.freeradbiomed.2007.04.028
Ledreux A, Boger HA, Hinson VK, Cantwell K, Granholm AC (2016) BDNF levels are increased by aminoindan and rasagiline in a double lesion model of Parkinson׳s disease. Brain Res 1631:34–45. https://doi.org/10.1016/j.brainres.2015.11.028
Lehmensiek V, Tan EM, Liebau S, Lenk T, Zettlmeisl H, Schwarz J, Storch A (2006) Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease. Neurochem Int 48:329–340. https://doi.org/10.1016/j.neuint.2005.11.008
Liang YO, Plotsky PM, Adams RN (1997) Isolation and identification of an in vivo reaction product of 6-hydroxydopamine. J Med Chem 20:581–583. https://doi.org/10.1021/jm00214a026
Liu J, Liu W, Yang H (2019) Balancing apoptosis and autophagy for Parkinson's disease therapy: targeting BCL-2. ACS Chem Neurosci 10:792–802. https://doi.org/10.1021/acschemneuro.8b00356
LoPachin RM, Geohagen BC, Gavin T (2009) Synaptosomal toxicity and nucleophilic targets of 4-hydroxy-2-nonenal. Toxicol Sci 107:171–181. https://doi.org/10.1093/toxsci/kfn226
Lossi L, Castagna C, Merighi A (2015) Neuronal cell death: an overview of its different forms in central and peripheral neurons. Methods Mol Biol 1254:1–18. https://doi.org/10.1007/978-1-4939-2152-2_1
Lotharius J, Dugan LL, O'Malley KL (1999) Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons. J Neurosci 19:1284–1293
Lushchak OV, Piroddi M, Galli F, Lushchak VI (2014) Aconitase post-translational modification as a key in linkage between Krebs cycle, iron homeostasis, redox signaling, and metabolism of reactive oxygen species. Redox Rep 19:8–15. https://doi.org/10.1179/1351000213Y.0000000073
Luthman J, Fredriksson A, Sundström E, Jonsson G, Archer T (1989) Selective lesion of central dopamine or noradrenaline neuron systems in the neonatal rat: motor behavior and monoamine alterations at adult stage. Behav Brain Res 33:267–277. https://doi.org/10.1016/s0166-4328(97)80991-6
Macinnes N, Duty S (2004) Locomotor effects of imidazoline I2-site-specific ligands and monoamine oxidase inhibitors in rats with a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathway. Br J Pharmacol 143:952–959. https://doi.org/10.1038/sj.bjp.0706019
Martinez B, Peplow PV (2018) Neuroprotection by immunomodulatory agents in animal models of Parkinson's disease. Neural Regen Res 13:1493–1506. https://doi.org/10.4103/1673-5374.237108
Masato A, Plotegher N, Boassa D, Bubacco L (2019) Impaired dopamine metabolism in Parkinson's disease pathogenesis. Mol Neurodegener 20(14):35. https://doi.org/10.1186/s13024-019-0332-6
Maurer JM, Schellekens RCA, van Rieke HM, Wanke C, Iordanov V et al (2015) Gastrointestinal pH and transit time profiling in healthy volunteers using the intellicap system confirms ileo-colonic release of ColoPulse tablets. PLoS ONE 10(7):e0129076. https://doi.org/10.1371/journal.pone.0129076
Mazzio EA, Reams RR, Soliman KF (2004) The role of oxidative stress, impaired glycolysis and mitochondrial respiratory redox failure in the cytotoxic effects of 6-hydroxydopamine in vitro. Brain Res. https://doi.org/10.1016/j.brainres.2003.12.034
Medda R, Calabrese L, Musci G, Padiglia A, Floris G (1996) Effect of ceruloplasmin on 6-hydroxydopamine oxidation. Biochem Mol Biol Int 38:721–728
Michel PP, Hefti F (1990) Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res 26:428–435. https://doi.org/10.1002/jnr.490260405
Miyama A, Saito Y, Yamanaka K, Hayashi K, Hamakubo T et al (2011) Oxidation of DJ-1 Induced by 6-hydroxydopamine decreasing intracellular glutathione. PLoS ONE 6(11):e27883. https://doi.org/10.1371/journal.pone.0027883
Moghe A, Ghare S, Lamoreau B, Mohammad M, Barve S, McClain C, Joshi-Barve S (2015) Molecular mechanisms of acrolein toxicity: relevance to human disease. Toxicol Sci 143:242–255. https://doi.org/10.1093/toxsci/kfu233
Monzani E, Nicolis S, Dell'Acqua S, Capucciati A, Bacchella C, Zucca FA, Mosharov EV, Sulzer D, Zecca L, Casella L (2019) Dopamine, oxidative stress and protein-quinone modifications in parkinson's and other neurodegenerative diseases. Angew Chem Int Ed Engl 58:6512–6527. https://doi.org/10.1002/anie.201811122
Murphy MP (2009) How mitochondria produce reactive oxygen species. Biochem J 417:1–13. https://doi.org/10.1042/BJ20081386
Napolitano A, Crescenzi O, Pezzella A, Prota G (1995) Generation of the neurotoxin 6-hydroxydopamine by peroxidase/H2O2 oxidation of dopamine. J Med Chem 38:917–922. https://doi.org/10.1021/jm00006a010
Nappi AJ, Vass E (1994) The effects of glutathione and ascorbic acid on the oxidations of 6-hydroxydopa and 6-hydroxydopamine. Biochim Biophys Acta 120:498–504. https://doi.org/10.1016/0304-4165(94)90082-5
Norenberg MD, Rama Rao KV, Jayakumar AR (2004) Ammonia neurotoxicity and the mitochondrial permeability transition. J Bioenerg Biomembr 36:303–307. https://doi.org/10.1023/B:JOBB.0000041758.20071.19
Ochu EE, Rothwell NJ, Waters CM (1998) Caspases mediate 6-hydroxydopamine-induced apoptosis but not necrosis in PC12 cells. J Neurochem 70:2637–2640. https://doi.org/10.1046/j.1471-4159.1998.70062637
Oestreicher F, Sengstock GJ, Riederer P, Olanow C, Dunn W, Arendash AJ (1994) Degeneration of nigrostriatial dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res 660:8–18
Ou XM, Lu D, Johnson C, Chen K, Youdim MBH, Rajkowska G, Shih JC (2009) Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res 16:148–159. https://doi.org/10.1007/s12640-009-9064-7
Padiglia A, Medda R, Lorrai A, Biggio G, Sanna E, Floris G (1997) Modulation of 6-hydroxydopamine oxidation by various proteins. Biochem Pharmacol 53(8):1065–1068. https://doi.org/10.1016/s0006-2952(96)00716-2
Palmer MJ, Hull C, Vigh J, von Gersdorff H (2003) Synaptic cleft acidification and modulation of short-term depression by exocytosed protons in retinal bipolar cells. J Neurosci 23:11332–11341
Park SH, Choi WS, Yoon SY, Ahn YS, Oh YJ (2004) Activation of NF-kappaB is involved in 6-hydroxydopamine-but not MPP+ -induced dopaminergic neuronal cell death: its potential role as a survival determinant. Biochem Biophys Res Commun 322:727–733. https://doi.org/10.1016/j.bbrc.2004.07.193
Park B, Oh CK, Choi WS, Chung IK, Youdim MBH, Oh YJ (2011) Microarray expression profiling in 6-hydroxydopamine-induced dopaminergic neuronal cell death. J Neural Transm (Vienna) 118:1585–1598. https://doi.org/10.1007/s00702-011-0710-x
Pathak RU, Davey GP (2008) Complex I and energy thresholds in the brain. Biochim Biophys Acta 777(7–8):777–782. https://doi.org/10.1016/j.bbabio.2008.05.443
Pezzella A, D'Ischia M, Napolitano A, Misuraca G, Prota G (1997) Iron-mediated generation of the neurotoxin 6-hydroxydopamine quinone by reaction of fatty acid hydroperoxides with dopamine: a possible contributory mechanism for neuronal degeneration in Parkinson's disease. J Med Chem 40:2211–2216. https://doi.org/10.1021/jm970099t
Pileblad E, Slivka A, Bratvold D, Cohen G (1988) Studies on the autoxidation of dopamine: interaction with ascorbate. Arch Biochem Biophys 263:447–452. https://doi.org/10.1016/0003-9861(88)90657-1
Plotegher N, Berti G, Ferrari E, Tessari I, Zanetti M, Lunelli L, Greggio E, Bisaglia M, Veronesi M, Girotto S, Dalla Serra M, Perego C, Casella L, Bubacco L (2017) DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function. Sci Rep 13(7):40699. https://doi.org/10.1038/srep40699
Pryor WA (1986) Oxy-cals and related species: their formation, lifetimes, and reactions. Annu Rev Physiol 48:657–667. https://doi.org/10.1146/annurev.ph.48.030186.003301
Radi R (2018) Oxygen radicals, nitric oxide, and peroxynitrite: redox pathways in molecular medicine. PNAS 115:5839–5848. https://doi.org/10.1073/pnas.1804932115
Radi R, Cassina A, Hodara R (2002) Nitric oxide and peroxynitrite interactions with mitochondria. Biol Chem. 383:401–409. https://doi.org/10.1515/BC.2002.044
Rajan KS, Davis JM, Colburn RW (1971) Metal chelates in the storage and transport of neurotransmitters: interactions of metal ions with biogenic amines. J Neurochem 18:345–364. https://doi.org/10.1111/j.1471-4159.1971.tb11963.x
Reid JJ, Stitzel RE, Head RJ (1986) Evidence that 6-hydroxydopamine is an inhibitor of catechol-O-methyltransferase in intact tissue. J Pharm Pharmacol 38:46–50. https://doi.org/10.1111/j.2042-7158.1986.tb04465.x
Rescigno A, Rinaldi AC, Sanjust E (1998) Some aspects of tyrosine secondary metabolism. Biochem Pharmacol 56:1089–1096. https://doi.org/10.1016/s0006-2952(98)00170-1
Riederer P, Laux G (2011) MAO-inhibitors in Parkinson's disease. Exp Neurobiol 20:1–17. https://doi.org/10.5607/en.2011.20.1.1
Riobó NA, Schöpfer FJ, Boveris AD, Cadenas E, Poderoso JJ (2002) The reaction of nitric oxide with 6-hydroxydopamine: implications for Parkinson's disease. Free Radic Biol Med 32:115–121. https://doi.org/10.1074/jbc.M204580200
Roginsky VA, Barsukova TK, Bruchelt G, Stegmann HB (1998) Kinetics of redox interaction between substituted 1,4-benzoquinones and ascorbate under aerobic conditions: critical phenomena. Free Radic Res 29:115–125. https://doi.org/10.1080/10715769800300131
Rosenberg PA (1988) Catecholamine toxicity in cerebral cortex in dissociated cell culture. J Neurosci 8:2887–2894. https://doi.org/10.1523/JNEUROSCI.08-08-02887.1988
Ross SB (1991) Synaptic concentration of dopamine in the mouse striatum in relationship to the kinetic properties of the dopamine receptors and uptake mechanism. J Neurochem 56:22–29. https://doi.org/10.1111/j.1471-4159.1991.tb02557.x
Rotman A, Daly JW, Creveling CR (1976) Oxygen-dependent reaction of 6-hydroxydopamine, 5,6-dihydroxytryptamine, and related compounds with proteins in vitro: a model for cytotoxicity. Mol Pharmacol 12:887–899
Sachs C, Jonsson G, Heikkila R, Cohen G (1975) Control of the neurotoxicity of 6-hydroxydopamine by intraneuronal noradrenaline in rat iris. Acta Physiol Scand 93:345–351. https://doi.org/10.1111/j.1748-1716.1975.tb05823.x
Sadeghian M, Mullali G, Pocock JM, Piers T, Roach A, Smith KJ (2016) Neuroprotection by safinamide in the 6-hydroxydopamine model of Parkinson's disease. Neuropathol Appl Neurobiol 42:423–435. https://doi.org/10.1111/nan.12263
Salonen T, Haapalinna A, Heinonen E, Suhonen J, Hervonen A (1996) Monoamine oxidase B inhibitor selegiline protects young and aged rat peripheral sympathetic neurons against 6-hydroxydopamine-induced neurotoxicity. Acta Neuropathol 91:466–474. https://doi.org/10.1007/s004010050453
Sánchez-Iglesias S, Rey P, Méndez-Alvarez E, Labandeira-García JL, Soto-Otero R (2007) Time-course of brain oxidative damage caused by intrastriatal administration of 6-hydroxydopamine in a rat model of Parkinson's disease. Neurochem Res 32:99–105. https://doi.org/10.1007/s11064-006-9232-6
Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD (1989) Mitochondrial complex ideficiency in Parkinson's disease. Lancet 1(8649):1269. https://doi.org/10.1111/j.1471-4159.1990.tb02325.x
Shendelman S, Jonason A, Martinat C, Leete T, Abeliovich A (2004) DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation. PLoS Biol 2:e362. https://doi.org/10.1371/journal.pbio.0020362
Singhal SS, Singh SP, Singhal P, Horne D, Singhal J, Awasthi S (2015) Antioxidant role of glutathione S-transferases: 4-hydroxynonenal, a key molecule in stress-mediated signaling. Toxicol Appl Pharmacol 289:361–370. https://doi.org/10.1016/j.taap.2015.10.006
Soto-Otero R, Méndez-Alvarez E, Hermida-Ameijeiras A, Muñoz-Patiño AM, Labandeira-Garcia JL (2000) Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease. J Neurochem 74:1605–1612. https://doi.org/10.1046/j.1471-4159.2000.0741605.x
Soto-Otero R, Méndez-Alvarez E, Hermida-Ameijeiras A, Sánchez-Sellero I, Cruz-Landeira A, Lamas ML (2001) Inhibition of brain monoamine oxidase activity by the generation of hydroxyl radicals: potential implications in relation to oxidative stress. Life Sci 69:889–989. https://doi.org/10.1046/j.1471-4159.2000.0741605.x
Souza JM, Radi R (1988) Glyceraldehyde-3-phosphate dehydrogenase inactivation by peroxynitrite. Arch Biochem Biophys 360:187–194. https://doi.org/10.1006/abbi.1998.0932
Stoppani AO, Milstein C (1957) Essential role of thiol groups in aldehyde dehydrogenases. Biochem J 67:406–416. https://doi.org/10.1042/bj0670406
Storch A, Kaftan A, Burkhardt K, Schwarz J (2000) 6-Hydroxydopamine toxicity towards human SH-SY5Y dopaminergic neuroblastoma cells: independent of mitochondrial energy metabolism. J Neural Transm (Vienna) 107:281–293. https://doi.org/10.1007/s007020050023
Storch A, Ludolph AC, Schwarz J (2004) Dopamine transporter: involvement in selective dopaminergic neurotoxicity and degeneration. J Neural Transm (Vienna) 111:1267–1286. https://doi.org/10.1007/s00702-004-0203-2
Sullivan SG, Stern A (1981) Effects of superoxide dismutase and catalase on catalysis of 6-hydroxydopamine and 6-aminodopamine autoxidation by iron and ascorbate. Biochem Pharmacol 30:2279–2285. https://doi.org/10.1016/0006-2952(81)90099-x
Sulzer D, Bogulavsky J, Larsen KE, Behr G, Karatekin E, Kleinman MH, Turro N, Krantz D, Edwards RH, Greene LA, Zecca L (2000) Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc Natl Acad Sci USA 97:11869–11874. https://doi.org/10.1073/pnas.97.22.11869
Szabó C, Ohshima H (1997) DNA damage induced by peroxynitrite: subsequent biological effects. Nitric Oxide 1:373–385. https://doi.org/10.1006/niox.1997.0143
Taskinen J, Ethell BT, Pihlavisto P, Hood AM, Burchell B, Coughtrie MW (2003) Conjugation of catechols by recombinant human sulfotransferases, UDP-glucuronosyltransferases, and soluble catechol O-methyltransferase: structure-conjugation relationships and predictive models. Drug Metab Dispos 31:1187–1197. https://doi.org/10.1124/dmd.31.9.1187
Tatton W, Chalmers-Redman R, Tatton N (2003) Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B. J Neural Transm (Vienna) 110:5009–5015. https://doi.org/10.1007/s00702-002-0827-z
Teixeira FG, Gago MF, Marques P, Moreira PS, Magalhães R, Sousa N, Salgado AJ (2018) Safinamide: a new hope for Parkinson's disease? Drug Discov Today 23:736–744. https://doi.org/10.1016/j.drudis.2018.01.033
Telford JE, Kilbride SM, Davey GP (2009) Complex I is rate-limiting for oxygen consumption in the nerve terminal. J Biol Chem 284:9109–9114. https://doi.org/10.1074/jbc.M809101200
Theodore S, Maragos W (2015) 6-Hydroxydopamine as a tool to understand adaptive immune system-induced dopamine neurodegeneration in Parkinson's disease. Immunopharmacol Immunotoxicol 37:393–399. https://doi.org/10.3109/08923973.2015.1070172
Thoenen H, Tranzer JP (1968) Chemical sympathectomy by selective destruction of adrenergic nerve endings with 6-Hydroxydopamine. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 261:271–288
Tieu K (2011) A guide to neurotoxic animal models of Parkinson’s disease. Cold Spring Harb Perspect Med 1:a009316. https://doi.org/10.1101/cshperspect.a009316
Tiffany-Castiglioni E, Saneto RP, Proctor PH, Perez-Polo JR (1982) Participation of active oxygen species in 6-hydroxydopamine toxicity to a human neuroblastoma cell line. Biochem Pharmacol 31:181–188. https://doi.org/10.1016/0006-2952(82)90208-8
Tipton KF (2018) 90 years of monoamine oxidase: some progress and some confusion. J Neural Transm (Vienna) 125:1519–1551. https://doi.org/10.1007/s00702-01
Tipton KF, Singer TP (1993) Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem 61:1191–1206. https://doi.org/10.1111/j.1471-4159.1993.tb13610.x
Tretter L, Adam-Vizi V (2000) Inhibition of Krebs cycle enzymes by hydrogen peroxide: a key role of [alpha]-ketoglutarate dehydrogenase in limiting NADH production under oxidative stress. J Neurosci 20:8972–8979. https://doi.org/10.1046/j.1471-4159.2002.01191.x
Turner AJ, Illingworth JA, Tipton KF (1974) Simulation of biogenic amine metabolism in the brain. Biochem J 144:353–360. https://doi.org/10.1042/bj1440353
Uchida K, Kanematsu M, Morimitsu Y, Osawa T, Noguchi N, Niki E (1988) Acrolein is a product of lipid peroxidation reaction. formation of free acrolein and its conjugate with lysine residues in oxidized low density lipoproteins. J Biol Chem 273:16058–16066. https://doi.org/10.1074/jbc.273.26.16058
Ungerstedt U (1968) 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 5:107–110. https://doi.org/10.1016/0014-2999(68)90164-167
Vaughan RA, Foster JD (2013) Mechanisms of dopamine transporter regulation in normal and disease states. Trends Pharmacol Sci 34:489–496. https://doi.org/10.1016/j.tips.2013.07.005
Villa M, Muñoz P, Ahumada-Castro U, Paris I, Jiménez A, Martinez SFI, Segura-Aguilar J (2013) One-electron reduction of 6-hydroxydopamine quinone is essential in 6-hydroxydopamine neurotoxicity. Neurotox Res 24:94–101. https://doi.org/10.1007/s12640-013-9382-7
Wang X, Michaelis EK (2010) Selective neuronal vulnerability to oxidative stress in the brain. Front Aging Neurosci 2:12. https://doi.org/10.3389/fnagi.2010.00012
Wang YT, Lin HC, Zhao WZ, Huang HJ, Lo YL, Wang HT, Lin AM (2017) Acrolein acts as a neurotoxin in the nigrostriatal dopaminergic system of rat: involvement of α-synuclein aggregation and programmed cell death. Sci Rep 7:45741. https://doi.org/10.1038/srep45741
Woodgate A, MacGibbon G, Walton M, Dragunow M (1999) The toxicity of 6-hydroxydopamine on PC12 and P19 cells. Brain Res Mol Brain Res 69:84–92. https://doi.org/10.1016/s0169-328x(99)00103-5
Youdim MBH, Grünblatt E, Mandel S (1999) The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson's disease with iron chelators. Ann N Y Acad Sci 890:7–25. https://doi.org/10.1111/j.1749-6632.1999.tb07977.x
Youdim MBH, Stephenson G, Shachar DB (2004) Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann N Y Acad Sci 1012:306–325. https://doi.org/10.1196/annals.1306.025
Zamzami N, Larochette N, Kroemer G (2005) Mitochondrial permeability transition in apoptosis and necrosis. Cell Death Differ 12:1478–1480. https://doi.org/10.1038/sj.cdd.4401682
Zhang H, Forman HJ (2017) Signaling by 4-hydroxy-2-nonenal: exposure protocols, target selectivity and degradation. Arch Biochem Biophys 617:145–154. https://doi.org/10.1016/j.abb.2016.11.003
Zhang Y, Marcillat O, Giulivi C, Ernster L, Davies KJ (1990) The oxidative inactivation of mitochondrial electron transport chain components and ATPase. J Biol Chem 265:16330–16336
Zhang J, Hu J, Ding JH, Yao HH, Hu G (2005) 6-Hydroxydopamine-induced glutathione alteration occurs via glutathione enzyme system in primary cultured astrocytes. Acta Pharmacol Sin 26:799–805. https://doi.org/10.1111/j.1745-7254.2005.00124.x
Zhang H, Li S, Wang M, Vukusic B, Pristupa ZB, Fang Liu F (2009) Regulation of dopamine transporter activity by carboxypeptidase E. Molecular Brain 2:10. https://doi.org/10.1186/1756-6606-2-10
Zheng H, Youdim MBH, Weiner FLM (2005) Synthesis and evaluation of peptidic metal chelators for neuroprotection in neurodegenerative diseases. J Peptide Res 66:190–203. https://doi.org/10.1111/j.1399-3011.2005.00289.x
Zhou W, Zhu M, Wilson MA, Petsko GA, Fink AL (2006) The oxidation state of DJ-1 regulates its chaperone activity toward alpha-synuclein. J Mol Biol 356:1036–1048. https://doi.org/10.1016/j.jmb.2005.12.030
Zucca FA, Basso E, Cupaioli FA, Ferrari E, Sulzer D, Casella L, Zecca L (2014) Neuromelanin of the human substantia nigra: an update. Neurotox Res 25:13–23. https://doi.org/10.1007/s12640-013-9435-y
Acknowledgements
We are grateful to the Science Foundation Ireland for support. KFT is grateful to Professor Moussa Youdim, for many wide-ranging and stimulating discussions.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Varešlija, D., Tipton, K.F., Davey, G.P. et al. 6-Hydroxydopamine: a far from simple neurotoxin. J Neural Transm 127, 213–230 (2020). https://doi.org/10.1007/s00702-019-02133-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-019-02133-6